{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:18:54Z","timestamp":1791033534383,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6794,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2001,6]]},"DOI":"10.1023\/a:1011180605373","type":"journal-article","created":{"date-parts":[[2002,12,23]],"date-time":"2002-12-23T06:26:45Z","timestamp":1040624805000},"page":"793-798","source":"Crossref","is-referenced-by-count":5,"title":["Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: A multicenter phase II study"],"prefix":"10.1016","volume":"12","author":[{"given":"A.","family":"Alexopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kouroussis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Malamos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kakolyris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kalbakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kosmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Mavroudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Agelaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vlachonicolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Rigatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Georgoulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1023\/A:1011180605373_bb0010","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","article-title":"Paclitaxel by three-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study","volume":"13","author":"Gianni","year":"1995","journal-title":"J Clin Oncol"},{"issue":"Suppl 11","key":"10.1023\/A:1011180605373_bb0015","first-page":"23","article-title":"Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer","volume":"23","author":"Dombernowsky","year":"1996","journal-title":"Semin Oncol"},{"issue":"Abstr","key":"10.1023\/A:1011180605373_bb0020","first-page":"27","article-title":"Final results of a phase II study of docetaxel, doxorubicin and cyclophosphamide (TAC) as first line chemotherapy in metastatic breast cancer","volume":"50","author":"Nabholtz","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.1023\/A:1011180605373_bb0025","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.1995.13.2.314","article-title":"Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer. A phase II trial of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer","volume":"13","author":"Chevalier","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011180605373_bb0030","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1200\/JCO.1996.14.1.58","article-title":"Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer","volume":"14","author":"Hudis","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011180605373_bb0035","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1200\/JCO.1995.13.12.2886","article-title":"Phase II trial of docetaxel. A new, highly effective anticancer drug","volume":"13","author":"Valero","year":"1995","journal-title":"J Clin Oncol"},{"issue":"4, Suppl 10","key":"10.1023\/A:1011180605373_bb0040","first-page":"S18","article-title":"Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer","volume":"24","author":"Ravdin","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1011180605373_bb0045","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group","volume":"17","author":"Chan","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011180605373_bb0050","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1200\/JCO.2000.18.4.724","article-title":"Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer. A European Organization for Research and Treatment of Cancer Randomized Study with cross-over","volume":"18","author":"Paridaens","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011180605373_bb0055","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1023\/A:1026418831238","article-title":"Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer","volume":"10","author":"Misset","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1011180605373_bb0060","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1023\/A:1026441804889","article-title":"Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study","volume":"10","author":"Kouroussis","year":"1999","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1023\/A:1011180605373_bb0065","first-page":"15","article-title":"Mitoxantrone as first-line chemotherapy for advanced breast cancer Results of a European Collaborative Study","volume":"11","author":"Smyth","year":"1984","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1011180605373_bb0070","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2165\/00003495-199141030-00007","article-title":"Mitoxantrone: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the chemotherapy of cancer","volume":"41","author":"Faulds","year":"1991","journal-title":"Drugs"},{"key":"10.1023\/A:1011180605373_bb0075","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1200\/JCO.1986.4.12.1827","article-title":"Use of in vitro dose-response effects to select antineoplastic drugs for high-dose or regional administration regimens","volume":"4","author":"Von Hoff","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011180605373_bb0080","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/JCO.1986.4.5.672","article-title":"A comparison of mitoxantrone and doxorubicin in breast cancer","volume":"4","author":"Neidhart","year":"1986","journal-title":"J Clin Oncol"},{"issue":"560","key":"10.1023\/A:1011180605373_bb0085","first-page":"571","article-title":"Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer","volume":"7","author":"Henderson","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011180605373_bb0090","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.1988.6.10.1611","article-title":"A randomized multicenter trial comparing mitoxantrone, cyclophosphamide and fluorouracil with doxorubicin, cyclophosphamide and fluorouracil in therapy of metastatic breast cancer","volume":"6","author":"Bennet","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011180605373_bb0095","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1023\/A:1006104610727","article-title":"Phase I\/II trial of high dose mitoxantrone in metastatic breast cancer: The M.D. Anderson Cancer Center experience","volume":"54","author":"Cristofanilli","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.1023\/A:1011180605373_bb0100","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0959-8049(97)10168-X","article-title":"A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer","volume":"34","author":"Gluck","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1023\/A:1011180605373_bb0105","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1200\/JCO.1999.17.3.862","article-title":"Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment with metastatic breast cancer","volume":"17","author":"Kouroussis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011180605373_bb0110","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1023\/A:1011180605373_bb0115","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"New parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1959","journal-title":"J Am Stat Assoc"},{"key":"10.1023\/A:1011180605373_bb0120","series-title":"Statistical Methods in Medical Research","author":"Armitage","year":"1990"},{"key":"10.1023\/A:1011180605373_bb0125","series-title":"The Analysis of Binary Data","author":"Cox","year":"1970"},{"key":"10.1023\/A:1011180605373_bb0130","first-page":"18","article-title":"Phase I\/II study with mitoxantrone\/docetaxel (NDOC) and phase III-study with mitoxantrone (N) vs. NDOC in patients with high risk locally advanced or metastatic breast cancer","author":"Loibl","year":"1999","journal-title":"Proc ASCO"},{"key":"10.1023\/A:1011180605373_bb0135","first-page":"18","article-title":"Mitoxantrone (Novantrone) and Paclitaxel combination chemotherapy in metastatic breast cancer","author":"Harvey","year":"1999","journal-title":"Proc ASCO"},{"issue":"Suppl 3","key":"10.1023\/A:1011180605373_bb0140","first-page":"S17","article-title":"Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group","volume":"24","author":"Panagos","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1011180605373_bb0145","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1200\/JCO.1993.11.7.1253","article-title":"Dose-response of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial","volume":"11","author":"Focan","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011180605373_bb0150","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.1996.14.4.1146","article-title":"Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group","volume":"14","author":"Bastholt","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011180605373_bb0155","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00001813-199703000-00006","volume":"8","author":"Colucci","year":"1997","journal-title":"Anti-Cancer Drugs"},{"key":"10.1023\/A:1011180605373_bb0160","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1008295427877","article-title":"Doubling epirubicin dose intensity (100 mg\/m2 versus 50 mg\/m2) in the FEC regimen significantly increases response rates. An international randomized phase II study in metastatic breast cancer","volume":"8","author":"Brufman","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1011180605373_bb0165","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/oxfordjournals.annonc.a010474","article-title":"Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients","volume":"7","author":"Honkoop","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1011180605373_bb0170","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.2000.18.12.2369","article-title":"Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group study E 1196","volume":"18","author":"Sparano","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011180605373_bb0175","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1200\/JCO.1997.15.5.1906","article-title":"Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer","volume":"15","author":"Gianni","year":"1997","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419479775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419479775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/12\/6\/793\/19479311\/12-6-793.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T01:59:00Z","timestamp":1582163940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419479775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["S0923753419479775"],"URL":"https:\/\/doi.org\/10.1023\/a:1011180605373","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}